Spots Global Cancer Trial Database for incomplete freund's adjuvant
Every month we try and update this database with for incomplete freund's adjuvant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma | NCT00091143 | Melanoma (Skin) | gp100 antigen incomplete Freu... keyhole limpet ... fludarabine pho... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00003222 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... sargramostim tetanus peptide... tyrosinase pept... | 18 Years - 79 Years | University of Virginia | |
| Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | NCT00077532 | Melanoma (Skin) | gp100 antigen incomplete Freu... ipilimumab | 16 Years - | National Institutes of Health Clinical Center (CC) | |
| Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | NCT00062036 | Melanoma (Skin) | aldesleukin filgrastim incomplete Freu... interleukin-2 g... therapeutic tum... cyclophosphamid... fludarabine pho... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00019994 | Melanoma (Skin) | MART-1 antigen aldesleukin gp100 antigen incomplete Freu... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer | NCT00079157 | Breast Cancer | incomplete Freu... sargramostim telomerase: 540... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma | NCT00357461 | Melanoma (Skin) | gp100:209-217(2... gp100:280-288(2... incomplete Freu... ipilimumab | 16 Years - | Bristol-Myers Squibb | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment | NCT00022438 | Melanoma (Skin) | aldesleukin incomplete Freu... recombinant tyr... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma | NCT00001703 | Renal Cell Carc... | incomplete Freu... von Hippel-Lind... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| p53 Vaccine for Ovarian Cancer | NCT00001827 | Ovarian Neoplas... | aldesleukin incomplete Freu... p53 peptide vac... sargramostim therapeutic aut... in vitro-treate... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00091338 | Melanoma (Skin) | MART-1 antigen gp100 antigen incomplete Freu... recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma | NCT00303836 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... fludarabine pho... therapeutic aut... in vitro-treate... gp100 antigen MART-1 antigen incomplete Freu... filgrastim aldesleukin | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | NCT00104780 | Lung Cancer | EP-2101 incomplete Freu... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | NCT00012246 | Colorectal Canc... Esophageal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Pancreatic Canc... Small Intestine... | carcinoembryoni... incomplete Freu... sargramostim | 18 Years - | The University of Texas Medical Branch, Galveston | |
| Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | NCT00706992 | Melanoma | ALVAC-MART-1 va... MART-1:26-35(27... Aldesleukin autologous anti... incomplete Freu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma | NCT00006385 | Melanoma (Skin) | MART-1 antigen gp100 antigen incomplete Freu... recombinant int... sargramostim tyrosinase pept... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00003568 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... | 16 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma | NCT00001703 | Renal Cell Carc... | incomplete Freu... von Hippel-Lind... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | NCT00118274 | Melanoma (Skin) | incomplete Freu... melanoma helper... multi-epitope m... tetanus toxoid ... cyclophosphamid... | 18 Years - 120 Years | University of Virginia | |
| Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | NCT00012246 | Colorectal Canc... Esophageal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Pancreatic Canc... Small Intestine... | carcinoembryoni... incomplete Freu... sargramostim | 18 Years - | The University of Texas Medical Branch, Galveston | |
| LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery | NCT00295958 | Melanoma (Skin) Non-melanomatou... | LMB-2 immunotox... MART-1 antigen gp100 antigen incomplete Freu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma | NCT00357461 | Melanoma (Skin) | gp100:209-217(2... gp100:280-288(2... incomplete Freu... ipilimumab | 16 Years - | Bristol-Myers Squibb | |
| Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | NCT00706992 | Melanoma | ALVAC-MART-1 va... MART-1:26-35(27... Aldesleukin autologous anti... incomplete Freu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy in Treating Patients With Melanoma | NCT00020358 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... tyrosinase pept... | 16 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | NCT00062036 | Melanoma (Skin) | aldesleukin filgrastim incomplete Freu... interleukin-2 g... therapeutic tum... cyclophosphamid... fludarabine pho... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy in Treating Patients With Melanoma | NCT00020358 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... tyrosinase pept... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma | NCT00003362 | Melanoma (Skin) | QS21 gp100 antigen incomplete Freu... sargramostim tyrosinase pept... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00079144 | Melanoma (Skin) | NY-ESO-1 peptid... aldesleukin filgrastim incomplete Freu... therapeutic aut... cyclophosphamid... fludarabine pho... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma | NCT00303836 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... fludarabine pho... therapeutic aut... in vitro-treate... gp100 antigen MART-1 antigen incomplete Freu... filgrastim aldesleukin | 18 Years - | National Cancer Institute (NCI) | |
| Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma | NCT00072085 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00003222 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... sargramostim tetanus peptide... tyrosinase pept... | 18 Years - 79 Years | University of Virginia | |
| Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | NCT01673217 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | decitabine NY-ESO-1 peptid... pegylated lipos... sargramostim incomplete Freu... immunohistochem... liquid chromato... mass spectromet... reverse transcr... laboratory biom... DNA methylation... enzyme-linked i... | 18 Years - | Roswell Park Cancer Institute | |
| Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | NCT01673217 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | decitabine NY-ESO-1 peptid... pegylated lipos... sargramostim incomplete Freu... immunohistochem... liquid chromato... mass spectromet... reverse transcr... laboratory biom... DNA methylation... enzyme-linked i... | 18 Years - | Roswell Park Cancer Institute | |
| Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome | NCT00513578 | Myelodysplastic... | PR1 leukemia pe... incomplete Freu... sargramostim | 18 Years - | National Cancer Institute (NCI) | |
| Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma | NCT00091143 | Melanoma (Skin) | gp100 antigen incomplete Freu... keyhole limpet ... fludarabine pho... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | NCT00118313 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim tetanus toxoid ... dimethyl sulfox... imiquimod adjuvant therap... | 12 Years - 120 Years | University of Virginia | |
| Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | NCT00030602 | Prostate Cancer | PSA prostate ca... incomplete Freu... | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | NCT00118313 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim tetanus toxoid ... dimethyl sulfox... imiquimod adjuvant therap... | 12 Years - 120 Years | University of Virginia | |
| Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma | NCT00019383 | Melanoma (Skin) | aldesleukin incomplete Freu... sargramostim tyrosinase pept... tyrosinase-rela... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | NCT00104780 | Lung Cancer | EP-2101 incomplete Freu... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment | NCT00022438 | Melanoma (Skin) | aldesleukin incomplete Freu... recombinant tyr... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00019994 | Melanoma (Skin) | MART-1 antigen aldesleukin gp100 antigen incomplete Freu... | 16 Years - | National Cancer Institute (NCI) | |
| Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00079144 | Melanoma (Skin) | NY-ESO-1 peptid... aldesleukin filgrastim incomplete Freu... therapeutic aut... cyclophosphamid... fludarabine pho... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma | NCT00071981 | Melanoma (Skin) | incomplete Freu... melanoma helper... multi-epitope m... sargramostim tetanus peptide... | 18 Years - | Eastern Cooperative Oncology Group | |
| Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | NCT00109811 | Adenocarcinoma ... Recurrent Prost... | PSA:154-163(155... incomplete Freu... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Novel Adjuvants for Peptide-Based Melanoma Vaccines | NCT00028431 | Melanoma | MDX-CTLA4 Antib... | 18 Years - | University of Southern California | |
| Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00091338 | Melanoma (Skin) | MART-1 antigen gp100 antigen incomplete Freu... recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | NCT00091104 | Melanoma (Skin) | MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer | NCT00091273 | Ovarian Cancer Primary Periton... | incomplete Freu... ovarian cancer ... sargramostim tetanus toxoid ... adjuvant therap... | 18 Years - | University of Virginia |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
